News for Halozyme Therapeutics, Inc. (HALO)

On June 30, 2025, BlackRock, Inc. (Trades, Portfolio) executed a notable transaction involving Halozyme Therapeutics Inc. The firm reduced its holdings in Haloz

PR NewswireSAN DIEGO, July 23, 2025 DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technologyApproval represents critical advan

PR NewswireSAN DIEGO, July 22, 2025 SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it wil

Goldman Sachs has restarted its analysis of Halozyme (HALO), assigning a Neutral rating and setting a price target of $55. The financial institution anticipates

Summary On June 20, 2025, Halozyme Therapeutics Inc (HALO) announced that the European Commission has approved VYVGART® 1000mg (efgartigimod alfa) for subcutan

PR NewswireSAN DIEGO, June 20, 2025 SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver,

Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here.

The United States Patent and Trademark Office's Patent Trial and Appeal Board has decided to review the patents held by Halozyme (HALO) at the request of Merck.

Wells Fargo analyst Mohit Bansal has highlighted a recent development where the Patent Trial and Appeal Board (PTAB) has initiated a patent review against Haloz

Looking into the current session, Halozyme Therapeutics Inc. HALO shares are trading at $53.85, after a 1.05% drop. Over the past month, the stock decreased by ...

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's s...

Halozyme Therapeutics (HALO) has received an analyst rating update from Morgan Stanley. The analyst, Vikram Purohit, has downgraded the stock from "Overweight"

Key Takeaways: Halozyme Therapeutics downgraded by Morgan Stanley, raising concerns over potential Medicare negotiations. Despite the downgrade, analysts

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

Morgan Stanley has revised its rating for Halozyme (HALO), moving it from Overweight to Equal Weight. The bank also adjusted the stock's price target from $73 t

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

Halozyme Therapeutics (HALO) saw its stock tumble significantly on Tuesday after Leerink downgraded its rating from Market Perform to Underperform, setting a ne